Drug Research
Velocity Clinical Research’s multi-site acquisitions signal new frontier for clinical site management industry
Velocity Clinical Research announces it has acquired two multi-site companies, VitaLink Research and the National Research Institute, for an undisclosed amount. The double acquisition...
Packaging & Labelling
BD Completes Study Investigating Performance of Glass Prefillable Syringes in Deep Cold Storage
BD (Becton, Dickinson and Company), a leading global medical technology company, completed a preliminary study investigating the impact of deep cold storage (-20°C and...
News
ConvaTec Enhances Innovation Management with Anaqua
Anaqua, the leading innovation and intellectual property management technology provider, announced that global medical products and technologies group ConvaTec will use Anaqua’s AQX platform...
Clinical Trials
Pfizer and BioNTech Announce Positive Topline Results From Pivotal Trial of COVID-19 Vaccine in Children 5 to 11 Years
Pfizer Inc. and BioNTech SE announced results from a Phase 2/3 trial showing a favorable safety profile and robust neutralizing antibody responses in children...
Drug Research
FDA Approves Samsung Bioepis and Biogens BYOOVIZ, LUCENTIS Biosimilar
Samsung Bioepis Co., Ltd. and Biogen Inc. announced that the U.S. FDA has approved BYOOVIZ (ranibizumab-nuna), a biosimilar referencing LUCENTIS® (ranibizumab)i , for the...
Press Releases
Celltrion’s regdanvimab becomes the first authorized COVID-19 treatment approved from the Korean MFDS
Celltrion Group announced that the Korean Ministry of Food and Drug Safety (MFDS) approved regdanvimab (CT-P59), a monoclonal antibody treatment for COVID-19 for the...
Clinical Trials
Valneva Completes Recruitment of Elderly Participants in Phase 3 Trial of its Inactivated COVID-19 Vaccine
Valneva SE, a specialty vaccine company, announced that it has completed recruitment of the initial cohort of elderly participants in Valneva’s Phase 3 trial,...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from up to 5 devices at once
Must read